Disc Medicine, Inc. Induced Conversion of Convertible Debt Expense
Disc Medicine, Inc. (IRON) reported Induced Conversion of Convertible Debt Expense of $0 for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:InducedConversionOfConvertibleDebtExpense · last filed 2022-11-10
- Disc Medicine, Inc. induced conversion of convertible debt expense for the quarter ending 2022-09-30 was $0.00.
- Disc Medicine, Inc. induced conversion of convertible debt expense for the quarter ending 2022-06-30 was $0.00.
- Disc Medicine, Inc. induced conversion of convertible debt expense for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Disc Medicine, Inc. induced conversion of convertible debt expense for the quarter ending 2021-12-31 was $0.00.
- Disc Medicine, Inc. induced conversion of convertible debt expense for fiscal 2021 was $711.00K.
| Period end | Induced Conversion of Convertible Debt Expense 3 month | Induced Conversion of Convertible Debt Expense 6 month | Induced Conversion of Convertible Debt Expense 9 month | Induced Conversion of Convertible Debt Expense 12 month |
|---|---|---|---|---|
| 2022-09-30 | $0.00 10-Q · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | $0.00 derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | $0.00 derived: sum of 3 quarters · filed 2022-08-11 | $0.00 derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-06 | $0.00 derived: sum of 2 quarters · filed 2022-05-06 | $0.00 derived: sum of 3 quarters · filed 2022-11-10 | $0.00 derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $0.00 derived: sum of 3 quarters · filed 2022-11-10 | $711.00K 10-K · filed 2022-03-10 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $711.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-11 | $711.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $711.00K 10-Q · filed 2022-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |